[1] Zhao, G.L.; Yu, L.M.; Gao, W.L.; Duan, W.X.; Jiang, B.; Liu, X.D.; Zhang, B.; Liu, Z.H.; Zhai, M.E.; Jin, Z.X.; Yu, S.Q.; Wang, Y. Berberine protects rat heart from ischemia/reperfusion injury via activating JAK2/STAT3 signaling and attenuating endoplasmic reticulum stress. Acta Pharmacol. Sin. 2016, 37, 354-367.
[2] Maxwell, S.R.; Lip, G.Y. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. Int. J. Cardiol. 1997, 58, 95-117.
[3] Park, J.L.; Lucchesi, B.R. Mechanisms of myocardial reperfusion injury. Ann Thorac. Surg. 1999, 68, 1905-1912.
[4] Murphy, E.; Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 2008, 88, 581-609.
[5] Jordan, J.E.; Zhao, Z.Q.; Vinten-Johansen, J. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc Res. 1999, 43, 860-878.
[6] Lam, F.F.; Yeung, J.H.; Cheung, J.H.; Or, P.M. Pharma-cological evidence for calcium channel inhibition by danshen (Salvia miltiorrhiza) on rat isolated femoral artery. J. Cardiovasc Pharmacol. 2006, 47, 139-145.
[7] Zhou, Y.; Li, W.; Xu, L.; Chen, L. In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid beta-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors. Environ. Toxicol. Pharmacol. 2011, 31, 443-452.
[8] Wong, K.K.; Ho, M.T.; Lin, H.Q.; Lau, K.F.; Rudd, J.A.; Chung, R.C.; Fung, K.P.; Shaw, P.C.; Wan, D.C. Cryptotanshinone, an acetylcholinesterase inhibitor from Salvia miltiorrhiza, ameliorates scopolamine-induced amnesia in Morris water maze task. Planta Med. 2010, 76, 228-34.
[9] Zhang, H.N.; An, C.N.; Zhang, H.N.; Pu, X.P. Protocatechuic acid inhibits neurotoxicity induced by MPTP in vivo. Neurosci Lett. 2010, 474, 99-103.
[10] Kang, D.G.; Oh, H.; Sohn, E.J.; Hur, T.Y.; Lee, K.C.; Kim, K J.; Kim, T.Y.; Lee, H.S. Lithospermic acid B isolated from Salvia miltiorrhiza ameliorates ischemia/reperfusion-induced renal injury in rats. Life Sci. 2004, 75, 1801-1816.
[11] Lin, Y.L.; Wu, C.H.; Luo, M.H.; Huang, Y.J.; Wang, C.N.; Shiao, M.S.; Huang, Y.T. In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells. J. Ethnopharmacol. 2006, 105, 215-222.
[12] Wu, Z.M.; Wen, T.; Tan, Y.F.; Liu, Y.; Ren, F.; Wu, H. Effects of salvianolic acid a on oxidative stress and liver injury induced by carbon tetrachloride in rats. Basic Clin. Pharmacol. Toxicol. 2007, 100, 115-120.
[13] Zhang, H.S.; Wang, S.Q. Salvianolic acid B from Salvia miltiorrhiza inhibits tumor necrosis factor-alpha (TNF-alpha)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species. J. Mol. Cell Cardiol. 2006, 41, 138-148.
[14] Tian X,X.W.; Ding X. Application of Danshen injection on early stage of renal transplantation. Chin. J. Integr. Med. 2005, 25, 404-407.
[15] O’Brien, K.A.; Ling, S.; Abbas, E.; Dai, A.; Zhang, J.; Wang, W.C.; Bensoussan, A.; Luo, R.; Guo, Z.X.; Komesaroff, P.A. A Chinese herbal preparation containing radix salviae miltiorrhizae, radix notoginseng and borneolum syntheticum reduces circulating adhesion molecules. Evid. Based Complement. Alternat. Med. 2011, 2011, 790784.
[16] Xu, W.; Yang, J.; Wu, L.M. Cardioprotective effects of tanshinone IIA on myocardial ischemia injury in rats. Pharmazie. 2009, 64, 332-336.
[17] Fu, J.; Huang, H.; Liu, J.; Pi, R.; Chen, J.; Liu, P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur. J. Pharmacol. 2007, 568, 213-221.
[18] Ren, Z.H.; Tong, Y.H.; Xu, W.; Ma, J.; Chen, Y. Tanshinone IIA attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine. 2010, 17, 212-218.
[19] Tong, Y.; Xu, W.; Han, H.; Chen, Y.; Yang, J.; Qiao, H.; Hong, D.; Wu, Y.; Zhou, C. Tanshinone IIA increases recruitment of bone marrow mesenchymal stem cells to infarct region via up-regulating stromal cell-derived factor-1/CXC chemokine receptor 4 axis in a myocardial ischemia model. Phytomedicine. 2011, 18, 443-450.
[20] Jun Song, L.; Xin, X.; Liu Qing, D.; Li Hua, C. Design of self-micro emulsifying drug delivery systems for tanshione IIA. Chin. J. New Drugs. 2010, 21, 1980-1985.
[21] Chen, K. The therapeutic effect of purified coronary heart II tablets on 112 cases of angina pectoris by double blind method. Chin. J. Integr. Tradit. West. Med. 1982, 10, 85-89.
[22] Shi, Y. Comparative Study of composite Danshen droplet pills and sordi in treatment of patients with chronic stable angina. Chin. J. Integr. Tradit. West. Med. 1997, 17, 23-25.
[23] Wei, B.; You, M.G.; Ling, J.J.; Wei, L.L.; Wang, K.; Li, W.W.; Chen, T.; Du, Q.M.; Ji, H. Regulation of antioxidant system, lipids and fatty acid beta-oxidation contributes to the cardioprotective effect of sodium tanshinone IIA sulphonate in isoproterenol-induced myocardial infarction in rats. Atherosclerosis. 2013, 230, 148-156.
[24] Liu, H.C.; Liu, H.H. Adverse reactions of tanshinone II(A) sodium sulfonate injection in treating 18 cases: an analysis of clinical features. Chin. J. Integr. Tradit. West. Med. 2013, 33, 1287-1289.
[25] Chen, J.K.; Shen, C.R.; Liu, C.L. N-acetylglucosamine: production and applications. Mar. Drugs. 2010, 8, 2493-2516.
[26] Ren-an, Q.; Juan, L.; Chuyuan, L.; Wenjuan, F.; Chunyan, H.; Xuemei, Y.; Lin, H.; Hong, N. Study of the protective mechanisms of Compound Danshen Tablet (Fufang Danshen Pian) against myocardial ischemia/reperfusion injury via the Akt-eNOS signaling pathway in rats. J. Ethnopharmacol. 2014, 156, 190-198.
[27] Pan, Y.; Qian, J.X.; Lu, S.Q.; Chen, J.W.; Zhao, X.D.; Jiang, Y.; Wang, L.H.; Zhang, G.X. Protective effects of tanshinone IIA sodium sulfonate on ischemia-reperfusion-induced myocardial injury in rats. Iran. J. Basic Med. Sci. 2017, 20, 308-315.
[28] Myska, J. Vysoka Skola Chem-Technol Prague Sb Vysoke Skoly Chem-Technol Praze. Org. Technol. 1961, 5219-5233.
[29] Gao, S.; Liu, Z.; Li, H.; Little, P.J.; Liu, P.; Xu, S. Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 2012, 220, 3-10.
[30] Hausenloy, D.J.; Mocanu, M.M.; Yellon, D.M. Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc. Res. 2004, 63, 305-312.
[31] Hausenloy, D.J.; Yellon, D.M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J. Clin. Invest. 2013, 123, 92-100.
[32] Gerczuk, P.Z.; Kloner, R.A. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J. Am. Coll. Cardiol. 2012, 59, 969-978.
[33] Kitakaze, M.; Asakura, M.; Kim, J.; Shintani, Y.; Asanuma, H.; Hamasaki, T.; Seguchi, O.; Myoishi, M.; Minamino, T.; Ohara, T.; Nagai, Y.; Nanto, S.; Watanabe, K.; Fukuzawa, S.; Hirayama, A.; Nakamura, N.; Kimura, K.; Fujii, K.; Ishihara, M.; Saito, Y.; Tomoike, H.; Kitamura, S.; investigators, J. W. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007, 370,1483-1493.
[34] Li, G.R.; Wang, H.B.; Qin, G.W.; Jin, M.W.; Tang, Q.; Sun, H.Y.; Du, X.L.; Deng, X.L.; Zhang, X.H.; Chen, J.B.; Chen, L.; Xu, X.H.; Cheng, L.C.; Chiu, S.W.; Tse, H.F.; Vanhoutte, P.M.; Lau, C.P. Acacetin, a natural flavone, selectively inhibits human atrial repolarization potassium currents and prevents atrial fibrillation in dogs. Circulation. 2008, 117, 2449-2457.
[35] Sofija, J.; Aleksandar, J. Models of cardioprotection. Drug Discovery Today: Disease Models. 2007, 4, 185-190.
[36] Kabay, S.; Ozden, H.; Guven, G.; Burukoglu, D.; Ustuner, M.C.; Topal, F.; Gunes, H.V.; Ustuner, D.; Ozbayer, C. Protective effects of the nuclear factor kappa B inhibitor pyrrolidine dithiocarbamate on experimental testicular torsion and detorsion injury. Korean J. Physiol. Pharmacol. 2014, 18, 321-326.
[37] Frank, A.; Bonney, M.; Bonney, S.; Weitzel, L.; Koeppen, M.; Eckle, T. Myocardial ischemia reperfusion injury: from basic science to clinical bedside. Semin Cardiothorac Vasc. Anesth. 2012, 16 , 123-132.
[38] Liu, H.; Yang, L.; Wu, H.J.; Chen, K.H.; Lin, F.; Li, G.; Sun, H.Y.; Xiao, G.S.; Wang, Y.; Li, G.R. Water-soluble acacetin prodrug confers significant cardioprotection against ischemia/reperfusion injury. Sci. Rep. 2016, 6, 36435.
[39] Heusch, G. Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res. 2015, 116, 674-699.
[40] Skyschally, A.; Gent, S.; Amanakis, G.; Schulte, C.; Kleinbongard, P.; Heusch, G. Across-Species Transfer of Protection by Remote Ischemic Preconditioning With Species-Specific Myocardial Signal Transduction by Reperfusion Injury Salvage Kinase and Survival Activating Factor Enhancement Pathways. Circ. Res. 2015, 117, 279-288.
[41] Liao, Y.F.; Zhu, W.; Li, D.P.; Zhu, X. Heme oxygenase-1 and gut ischemia/reperfusion injury: A short review. World J. Gastroenterol. 2013, 19, 3555-3561.
[42] An, L.; Liu, C.T.; Yu, M.J.; Chen, Z.H.; Guo, X.G.; Peng, W.; Wang, J.F.; Fang, X.Q.; Gao, Y.H.; Yu, S.Y. Heme oxygenase-1 system, inflammation and ventilator-induced lung injury. Eur. J. Pharmacol. 2012, 677, 1-4.
[43] Paine, A.; Eiz-Vesper, B.; Blasczyk, R.; Immenschuh, S. Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem. Pharmacol. 2010, 80, 1895-1903.
[44] Aztatzi-Santillan, E.; Nares-Lopez, F.E.; Marquez-Valadez, B.; Aguilera, P.; Chanez-Cardenas, M.E. The protective role of heme oxygenase-1 in cerebral ischemia. Cent. Nerv. Syst. Agents Med. Chem. 2010, 10, 310-316.
[45] Ryter, S.W.; Choi, A.M. Heme oxygenase-1/carbon monoxide: novel therapeutic strategies in critical care medicine. Curr. Drug Targets. 2010, 11, 1485-1494.
[46] Yeh, C.H.; Chen, T.P.; Wang, Y.C.; Lin, Y.M.; Lin, P.J. HO-1 activation can attenuate cardiomyocytic apoptosis via inhibition of NF-kappaB and AP-1 translocation following cardiac global ischemia and reperfusion. J. Surg. Res. 2009, 155, 147-156. |